

North American Congress of Clinical Toxicology

Organized By The American Academy of Clinical Toxicology



SHERATON VANCOUVER WALL CENTRE

PRE-MEETING - OCTOBER 11-12, 2017
MAIN CONGRESS - OCTOBER 13-15, 2017

Sponsored By:

- American Academy of Clinical Toxicology
- American Association of Poison Control Centers

With Content Provided By:

- American Academy of Clinical Toxicology
- American Association of Poison Control; Centers
- American Board of Applied Toxicology
- American College of Medical Toxicology
- Canadian Association of Poison Control Centres
- European Association of Poisons Centres and Clinical Toxicologists
- Asia Pacific Association of Medical Toxicology

Conference
Schedule

Continuing
Education



NACCT

North American Congress of Clinical Toxicology 2017

**Sheraton Wall Centre
October 11-15, 2017**

Sponsored by:

*American Academy of Clinical Toxicology
American Association of Poison Control Centers*

Collaborating Associations:

*American College of Medical Toxicology
Canadian Association of Poison Control Centres
European Association of Poisons Centres and Clinical Toxicologists
Asia Pacific Association of Medical Toxicology*

Organized by:

The American Academy of Clinical Toxicology & The American Association of Poison Control Centers

Meeting Chairs:

*Mark Kostic, MD, President-Elect, AACT
Mark Ryan, PharmD, President-Elect, AAPCC*

Scientific Advisory Council:

*Jon B. Cole, MD Co-Chair
Brandon Wills, DO, Co-Chair
Kennon Heard, MD, PhD
Christina Hantsch Bardsley, MD
Margaret Thompson, MD
Nicholas Buckley, MD
Bruno Megarbane, MD, PhD
Alfred Aleguas, PharmD
Howard McKinney, PharmD*

Finance & Sponsorship:

*Shawn Varney, MD
Sarah Shiffert*

Continuing Health Care

Professional Education Committee:

*Kirk Cumpston, DO
Nadia Awad, PharmD
Renee Petzel Gimbar, PharmD*

Abstract Selection Committee:

*John Devlin, MD, Chair
Ziad Kazzi, MD, Co-Chair*

Scheduling:

Sandy Giffin, MS, RN

Public Education Committee:

*Gayle Finkelstein, RN
Stefanie Baines, CHES*

Specialist in Poison Information Committee:

*Jamie Nisbet, RN, MSN, CSPI
Randy Badillo, RN, BSN, CSPI*

With Special Thanks To:

*Leigh De La Torre & Alli Bamer, Elaine White, Contemporary Forums
Rob Palmer, PhD President, AACT
Sarah Shiffert, Executive Director, AACT
Nakera Dumas, Executive Assistant, AACT
William Banner, MD, President, AAPCC
Stephen Kaminski, JD, CEO, Executive Director, AAPCC*

2017 NORTH AMERICAN CONGRESS OF CLINICAL TOXICOLOGY

Vancouver, BC

October 11 - 15, 2017

Welcome to the North American Congress of Clinical Toxicology (**NACCT**). The American Academy of Clinical Toxicology (AACT) and American Association of Poison Control Centers (AAPCC) are pleased to be your hosts for the 2017 NACCT meeting in Vancouver, BC. We hope that you find this a valuable educational experience as well as an enjoyable visit to Vancouver. Contemporary Forums staff will be assisting the host associations. If you need any assistance, please do not hesitate to contact a staff member in the office located on the North Tower Lower Lobby.

CONTINUING EDUCATION

If you have paid for CE credit, please remember to complete your online evaluations, attendance forms, and also print your Continuing Education Certificate at the end of the meeting. If you have not paid for CE credit and would like to do so, please stop by the NACCT registration desk at your earliest convenience.

NACCT will be utilizing CPE Monitor for tracking and reporting all ACPE-accredited continuing pharmacy education activities. Pharmacists are required to complete their e-profile at www.nabp.net in order to obtain a NABP e-Profile ID. Please remember that you will need to submit the NABP e-profile ID and your birthdate in order to receive CPE credit for NACCT 2017.

In order to obtain continuing education credit, evaluations must be completed after attendance of continuing education sessions held at NACCT. Individuals who do not complete the evaluations within 30 days of the meeting will not receive continuing education credit through NABP.

Name badges must be worn at all times to enter the Symposia, Exhibits, and Poster Sessions. Out of consideration to others, infants, children and spouses are not permitted in the sessions or refreshment areas.

ACMT Pre-Symposium: “Up for Debate: Addressing Controversies in Poisoning” Registration/Check-In will be held on **Wednesday, October 11, 7:00 - 8:00 a.m.**

AACT Pre-Symposium: “Cardiotoxins: An in-depth look at the Pathophysiology, Presentation, and Management of Heart Poisoning” Registration/Check-In will be held on **Thursday, October 12, 7:00 - 8:00 a.m.**

NACCT 2017 Main Congress Registration/Check-In will be held on **Thursday, October 12, 1:00 - 5:00 p.m.** and **Friday, October 13, 7:00 a.m. - 5:00 p.m.**

RETRIEVING SPEAKER HANDOUTS:

Speaker **handouts** will be available for download beginning October 2, 2017. Please check www.prolibraries.com/nacct/redeem or the NACCT Mobile App for the most current lecture handouts as the content is periodically updated. If using the Prolibraries website, the redeem code is NACCT17

TAYLOR & FRANCIS CLINICAL TOXICOLOGY JOURNAL:

The hard-bound edition of the journal *Clinical Toxicology* will **not be distributed onsite.** Please download the PDF file of the abstracts prior to arriving at the conference, or view the abstracts *via* the NACCT Mobile App.

PRESENTERS

All presenters are asked to arrive at least 15 minutes prior to their scheduled presentation time. **All presentations will be uploaded to the conference laptops in advance. Any updated presentations must be submitted as soon as possible on a flash drive to the conference registration desk. Poster presenters should note the appropriate poster set-up times in the meeting schedule. Please be certain to remove your poster within 30 minutes following your session to facilitate set-up for the next group.**

MEALS

Continental Breakfast is available for meeting registrants only, Friday – Sunday 7:00 - 8:00 a.m. in Grand Ballroom Foyer. Beverages for mid-morning and afternoon breaks will be served in the exhibit/poster area, Pavilion Ballroom 3rd Floor South Tower. While a few selected sessions do include a meal, most congress participants are responsible for their own lunch. Restaurant listings are available in the registration area and in the NACCT Mobile App. The hotel concierge/guest services agents are also happy to assist you in finding the perfect restaurant.

KEYNOTE PRESENTATION AND BREAKFAST

The NACCT Keynote Presentation will be **Friday, October 13** with a Continental Breakfast served from **7:00 – 8:00 a.m.**, and the Keynote Presentation beginning promptly at **8:00 a.m.** in the **Grand Ballroom**.

The Keynote Speaker, Jennifer Gardy, is a senior scientist at the British Columbia Centre for Disease Control where she hunts for the newest deadly diseases before they spread. In her talks, and in her work as a guest host on the Nature of Things, a Canadian television series of scientific documentaries.

OPENING RECEPTION

The Opening Reception will be held on **Friday, October 13, from 5:15 - 6:15 p.m.** in the Grand Ballroom Foyer. Anyone who is not registered for the NACCT and who wishes to attend the Opening Reception, will be required to pay a one-time \$60.00 “Accompanying Person/Guest” fee.

Science World at Telus World of Science TOUR & DINNER

The Tour & Dinner will be held on **Saturday, October 14, from 6:30 - 10:30 p.m.** Transportation will be provided from the South Tower hotel entrance beginning at 5:45 p.m. You will board coach busses which will transport you to the venue. The last coach bus will depart the hotel at 6:30 p.m. Please bring your dinner and drink ticket with you to the event. Tours of the Science World will begin as you arrive and will be open for private viewing until 9:30 p.m. Dinner will be served at 7:30 p.m. in the Rotunda. Coach busses will begin boarding at 9:30 p.m. for transportation back to the hotel. The last coach bus will depart the Science World at 10:00 p.m.

ONLINE LIBRARY

To be sure you receive the speakers’ most current information in an environmentally-friendly way, the recorded conference sessions and PowerPoint slides will be available to you online on a complimentary basis. Your tuition includes access to the Online CE Library for the all Main Congress recorded sessions for which you registered.

Approximately three weeks after the meeting you will receive an ***email*** notifying you that the presentations recorded at the live conference, along with the synchronized PowerPoint slides, are available to access in the Online Library. Please make sure your email address is correct in your registration materials refer to “Online Library-Open 24/7!” in this Conference Guide for your log-in code and additional details about this valuable educational resource. Digitell representatives will be available on-site to assist you.

NACCT MOBILE APP

Download the NACCT Mobile App from the Apple or Google Play stores so you can stay current with real-time conference updates and notifications. Search “NACCT” in your provider’s app store. You will find a complete schedule, full-text abstracts, speaker handouts, and additional conference information all only a tap away. After you download the app, you will login using your email address and a registration code. The code is your first initial followed by your last name (all lower case, no spaces, hyphens or apostrophes- e.g., Joe Smith is “jsmith”). You should receive an email from CrowdCompass with your registration code as confirmation. You can also access the app by going to <https://crowd.cc/nacct17>.

New This Year

To accommodate our ever-shortening attention spans, most speakers will be giving 25-30 minute presentations instead of an hour. The overall amount of learning and CE available will remain the same as in years’ past, just presented in a more compact and hopefully more useful, manner.

Following each “Authors with Posters” session, there will be a ½ hour of “Lightning Orals” where some of our strongest posters are presented again but in a brief Power Point format, in a more intimate setting. This will hopefully allow for even better discussion and perspective.

And finally, in an attempt to highlight a current controversy in the management of poisoned patients, NACCT will feature a debate between leaders in our field. This year’s topic is the optimal manner in which to pharmaceutically restrain an agitated, dangerous patient.

MESSAGES & PARTICIPANT ROSTER

The message board located near the NACCT Registration Desk is available for messages and announcements, and includes the pre-registered participant list. Please check this message board, and the mobile app, for important meeting updates.

TOBACCO USE RESTRICTIONS

It is the policy of The Sheraton Hotel that smoking, including use of vaping devices, and use of chewing tobacco is not permitted in the meeting rooms, around the NACCT Registration Desk, Exhibit/Poster space or refreshment break areas. Thank you for your cooperation.

PERSONAL BELONGINGS

Please be sure to take all personal belongings (e.g., jackets, tote bags, laptops, notebooks, etc.) with you when leaving the meeting rooms. NACCT cannot assume responsibility for lost or stolen articles.

TOURIST INFORMATION

Tourist information is offered by the **Tourism Vancouver** at <https://www.tourismvancouver.com> or **(604)682-2222**

The hosts and participants of NACCT gratefully acknowledge the contributions of the meeting Sponsors:

BTG International Inc.

2017 NACCT Abstract Reviewers
Co-Chairs: John Devlin & Ziad Kazzi

Reviewers:	
Cynthia	Aaron
Steve	Aks
Adam	Algren
Bruce	Anderson
Debbie	Anderson
Patil	Armenian
Justin	Arnold
Vik	Bebarta
John	Benitez
Doug	Borys
Jeffrey	Brent
Jennie	Buchanan
Lee	Cantrell
Daniel	Cobaugh
Jon	Cole
Kirk	Cumpston
Paul	Dargan
Michael	Darracq
John	Devlin
Natalija	Farrell
Sophie	Gosselin
Kennon	Heard
Christopher	Holstege
David	Juurlink
Louise	Kao
Ziad	Kazzi
Kurt	Kleinschmidt
Hugo	Kupferschmidt
Dayne	Laskey
Joe	Maddry
Bruno	Megarbane
Maria	Mercurio-Zappala
Jill	Michels
Mark	Mycyk
Kristine	Nanagas
Tammy	Noble
Sean	Nordt
Anthony	Pizon
Mohan	Punja
Becky	Rosier
Tammi	Schaeffer
Elizabeth	Scharman
Lauren	Schwartz
Kerry	Schwarz
Dan	Sessions
Mazda	Shirazi
Rick	Spiller
Matthew	Stanton
Sam	Stellpflug
Andrew	Stolbach
Christine	Stork
Mark	Su
Margaret	Thompson
Chris	Tomaszewski
Laura	Tormoehlen
Shawn	Varney
Steve	Walsh
Richard	Wang
Tim	Wiegand
Brandon	Wills
Alan	Woolf
Luke	Yip

Exhibitor List NACCT - 2017

- An open source collaborative project
- American Board of Applied Toxicology (ABAT)
- Advanced Hazmat Life Support
- American Academy of Clinical Toxicology (AACT)
- American Association of Poison Control Center (AAPCC)
- American College of Medical Toxicology (ACMT)
- Arbor Pharmaceuticals
- BTG International Inc.
- g.s innovations
- National Library of Medicine
- National Poisons Information Service (Edinburgh)
- Rocky Mountain Poison & Drug Center (RMPDC) Denver Health
- Springer International Publishing
- Taylor & Francis
- Texas Tech University Health Sciences Center El Paso
- Toxinz Poisons Information
- Wondfo USA

Conference Schedule

7:00 am – 5:00 pm North Tower Lower Lobby	ACMT Pre-Symposium Registration / Information
7:00 am – 8:00 am Junior Ballroom Foyer 3 rd Floor North Tower	Continental Breakfast
8:00 am – 5:30 pm Junior Ballroom 3 rd Floor North Tower	ACMT Pre-Symposium: Up for Debate: Addressing Controversies in Poisoning Moderators: Christina Hantsch Bardsley, MD Diane Calello, MD Spencer Greene, MD, MS Heather Long, MD <i>Presentations:</i> <i>Grease is the Word: In Favor of Lipid Emulsion Therapy</i> <i>Ann-Jeannette Geib, MD</i> <i>The Low-Fat Perspective: Against Lipid Emulsion Therapy</i> <i>Michael Levine, MD</i> <i>Specific Pediatric: Considerations in Lipid Therapy</i> <i>Diane Calello, MD</i> <i>Lipid Therapy: Case-Based Discussion</i> <i>Ann-Jeannette Geib, MD</i> <i>Michael Levine, MD</i> <i>Diane Calello, MD</i> <i>Decisions, Decisions: Renal Replacement Modalities in Poisoning</i> <i>Josh King, MD</i> <i>RRT in Chronic Lithium Toxicity: What is the Evidence?</i> <i>Darren Roberts, MD, PhD</i> <i>RRT in Acetaminophen-Induced Hepatic Failure: Pros and Cons</i> <i>Sophie Gosselin, MD</i>

<i>Decision Making in Dialysis: Case Based Discussion</i> <i>Josh King, MD</i> <i>Darren Roberts, MD, PhD</i> <i>Sophie Gosselin, MD</i> <i>Diane Calello, MD</i> <i>In the News: How lead in Flint, MI, Opened the Public's Eyes</i> <i>Bryan Judge, MD</i> <i>Cynthia Aaron, MD</i> <i>Lead in the Water: Drink Up?</i> <i>William Banner, MD, PhD</i> <i>Lead in the Water: Don't Swallow!</i> <i>Michael Kosnett, MD, MPH</i> <i>Nar-CAN Go: Fast and Furious</i> <i>Alison Jones, MD</i> <i>Low Dose Naloxone: Slow and Steady Wins the Race</i> <i>Rob Hendrickson, MD</i> <i>CNS Depression Re-Versed</i> <i>Christina Hantsch Bardsley, MD</i> <i>Flumaz-evil: Keep It Out of My Coma Cocktail</i> <i>Marco Sivilotti, MD</i> <i>The Best Part of Waking Up (An Antimuscarinic Patient) is With Physostigmine in Your Cup</i> <i>Spencer Greene, MD</i> <i>Anti Antillirium</i> <i>Brenna Farmer, MD</i>

- At the end of this session, the participant should be able to:
1. Describe beneficial effects of lipid emulsion therapy on survival from cardio active drug poisoning.
 2. Name hemodynamic parameters favorably affected by intravenous lipid emulsion.
 3. Understand the rationale for the use of vasopressors in the treatment of calcium channel blocker overdose.
 4. Discuss why one may choose vasopressors over high dose insulin.
 5. Identify the adverse effects of lipid emulsion therapy, especially in pediatrics.
 6. Discuss the risk: benefit ratio for lipid emulsion therapy in poisoning.
 7. Describe the different modalities of renal replacement therapy used for the treatment of the poisoned patient.
 8. Understand the pharmacokinetic factors which affect extracorporeal removal of toxins.
 9. Describe anticipated benefits from the use of renal replacement therapies in toxicology.
 10. Describe occasions when renal replacement therapy will not be advantageous in toxicology.
 11. Discuss the evidence behind the use of renal replacement therapies in acetaminophen hepatotoxicity.
 12. Discuss the water crisis in Flint, Michigan.
 13. Understand the basis for concerns regarding low level exposure to lead.
 14. Recognize the limited contribution of lead in drinking water to blood lead.
 15. Recognize the limited contribution of lead in drinking water to blood lead.
 16. Recognize the strength of causal evidence linking low level lead exposure to adverse cognitive effects in children.
 17. Understand clinical indications for consideration of higher doses of naloxone.
 18. Minimize naloxone-associated side effects while treating opioid overdoses.
 19. Identify clinical situations in which use of flumazenil is likely to be beneficial.
 20. Justify the avoidance of the routine use of flumazenil for CNS depression following overdose.
 21. Discuss potential adverse effects of flumazenil use.
 22. Identify the situations where physostigmine is indicated.
 23. Recognize legitimate contraindications to the use of physostigmine.
 24. Discuss when physostigmine should not be used.

- 8:00 am – 5:00 pm

AACT Board Meeting

Finback

3rd Floor South Tower
- 12:00 pm – 6:00 pm

ABAT Exam (Part 1)

Beluga

3rd Floor South Tower
- 5:00 pm – 9:00 pm

ABAT Board Meeting (Part 1)

Orca

3rd Floor South Tower

Rooms	7:00 am	7:30 am	8:00 am	8:30 am	9:00 am	9:30 am	10:00 am	10:30 am	11:00 am	11:30 am	12:00 pm	12:30 pm	1:00 pm	1:30 pm	2:00 pm	2:30 pm	3:00 pm	3:30 pm	4:00 pm	4:30 pm	5:00 pm	5:30 pm	6:00 pm	6:30 pm	7:00 pm	7:30 pm	8:00 pm	8:30 pm	9:00 pm																
North Tower Lower Lobby	ACMT Pre-Symposium Registration																																												
Junior Ballroom 3rd Floor North Tower			ACMT Pre-Symposium: Up for Debate: Addressing Controversies in Poisoning																																										
Finback 3rd Floor South Tower			**AACT Board Meeting**																																										
Orca 3rd Floor South Tower																					**ABAT Board Meeting (Part 1)**																								
Beluga 3rd Floor South Tower											**ABAT Exam (Part 1) **																																		
	Color Key			Main Symposium			AAPCC			ACMT			AACT			ABAT			MISC			**Private**			PEC			AHLS																	
	** Denotes Restricted Attendance to members/invitees only**																																												
	Room Names Subject to Change																																												

7:00 am – 1:00 pm
North Tower Lower Lobby

AACT Pre-Meeting Symposium Registration / Information

7:00 am – 8:00 am
Junior Ballroom Foyer
3rd Floor North Tower

Continental Breakfast

8:00 am – 5:00 pm
Junior Ballroom
3rd Floor North Tower

AACT Pre-Symposium: *Cardiotoxins an in-depth Look at the Pathophysiology, Presentation, and Management of Heart Poisoning*
Moderators: Brandon Willis, DO
Kennon Heard, MD, PhD

Presentations:
The Potassium Channel
Alex Manini, MD

The Calcium Channel
Jason Chu, MD

Pathophysiology of Gap Junctions and QRS Prolongation
Robert S. Hoffman, MD

Coronary Artery Disease
James Cao, MD

Debate: HDI vs Vasopressors
Kristen Engebretsen, PharmD
Samuel Stellpflug, MD
Michael Levine, MD
Meghan Spyres, MD

Drug-Induced Cardiomyopathy (more chronic)
Philippe Hantson, MD, PhD

Drug-Induced Takotsubo Cardiomyopathy
Tammi Schaeffer, DO

Natural Cardiotoxins
Sophie Gosselin, MD

Central Alpha-2 Agonists
Ben Hatten, MD, MPH

Panel: Debate: Ethics of Using Antidotes With No Quality Human Data
Marco Sivilotti, MD
Craig Smollin, MD
Jeffrey Brent, MD, PhD

At the end of this session, the participant should be able to:

1. Understand how toxins modify the cardiac action potential by interference with potassium channels.
2. Discuss how certain ECG findings dictate management of the poisoned patient.
3. Describe the pathophysiology of L-type and ryanodine receptors blockade and targeted therapies to reverse toxicity.
4. Explain the role that different junctions serve in cellular communication.
5. Compare conductance through the gap junction with traditional sodium channels and voltage dependent calcium channels.
6. Review toxicological causes of acute coronary syndrome.
7. Discuss the evidence associating cocaine with acute coronary syndrome.
8. Discuss the data supporting the use of insulin or vasopressors in toxin induced cardiovascular shock.
9. Identify the differences between animal data and human data supporting the use of HIE in toxin induced CV shock.
10. Compare the use of insulin to vasopressors for treatment of calcium channel blocker poisoning.
11. Understand the rationale for the use of vasopressors in the treatment of calcium channel blocker overdose.
12. Discuss why one may choose vasopressors over high dose insulin.
13. Discuss the pathophysiology of energetic failure in drug-induced cardiomyopathy.
14. Understand the role of metabolic therapies versus cardiotropic drugs.
15. Discuss the epidemiology and pathophysiology of drug-induced Takotsubo's cardiomyopathy.

Thursday, October 12, 2017 (continued)

Conference Schedule

16. Discuss the clinical presentation and treatment of drug-induced Takotsubo's cardiomyopathy.
17. Describe the pathophysiology of various cardiotoxins encountered in nature and their broad classification.
18. Recognize the clinical patterns of potential natural cardiotoxins to formulate a treatment strategy.
19. Describe the receptor interactions in cases of alpha-2 agonist exposure.
20. Describe the clinical syndrome associated with alpha-2 agonist toxicity.
21. Discuss possible approaches to informing patients of treatment options when there are no high-quality studies on the disease.

8:00 am – 1:00 pm Beluga 3rd Floor South Tower	*ABAT Exam* (Part 2)
8:00 am – 5:00 pm Port Hardy 4th Floor North Tower	*ACMT Board Meeting*
8:00 am – 5:00 pm Orca 3rd Floor South Tower	*ABAT Board Meeting* (Part 2)
11:30 am – 5:00 pm Finback 3rd Floor South Tower	*AAPCC Board Meeting* (Part 1)
1:00 pm – 6:00 pm North Tower Lower Lobby	NACCT Conference Registration / Information
1:00 pm – 5:00 pm Pavilion Ballroom 3rd Floor South Tower	Exhibitor Set - Up
1:00 pm – 5:00 pm Pavilion Ballroom 3rd Floor South Tower	Poster Session I Set-Up - Abstracts # 29-114

Thursday, October 12, 2017 (continued)

Conference Schedule

3:30 pm – 10:00 pm Parksville 3rd Floor North Tower	* AAPCC Accreditation Meeting *
4:00 pm – 7:00 pm Port Alberni 4th Floor North Tower	AAPCC SPI Committee Meeting
5:00 pm – 6:00 pm Galiano 4th Floor South Tower	AAPCC Benchmarking / QA Meeting
5:00 pm – 6:00 pm Beluga 3rd Floor South Tower	PEC Educator Meet and Greet
5:00 pm – 6:00 pm Port Hardy 4th Floor North Tower	AAPCC Surveillance Team
6:00 pm – 7:00 pm Orca 3rd Floor South Tower	PEC Opening Meeting / Committee Reports <i>Presentations: Wendy Stephan. MPH, PhD Candidate Maria Chapman, BA</i>
5:00 pm – 7:00 pm Junior Ballroom 3rd Floor North Tower	ACMT Medical Toxicology: 19th Annual Clinical Pathophysiology Competition (CPC) Moderator: Jeffrey R. Suchard, MD

- At the end of the session, the participant should be able to:
1. Formulate an approach to the diagnosis of complex poisoning cases based on limited data.
2. Describe the management of several unique poisonings.
3. Identify potential pitfalls in the diagnostic approach to poisoned patients.

Thursday, October 12, 2017 (continued)

Conference Schedule

6:30 pm – 8:00 pm Finback 3 rd Floor South Tower	CAPCC Business Meeting
7:00 pm – 8:00 pm Orca 3 rd Floor South Tower	PEC Steering Committee Meeting <i>Presentations: Maria Chapman, MA Nikesha Yarbrough, BS</i>
6:00 pm – 7:00 pm Galiano 4 th Floor South Tower	AAPCC Truven Joint Coding Committee Meeting
7:00 pm - 8:00 pm Port Hardy 4 th Floor North Tower	AAPCC NPDS Updates Meeting
7:00 pm – 8:00 pm Port McNeil 4 th Floor North Tower	AACT Business & Membership Meeting
8:00 pm – 9:00 pm Port McNeil 4 th Floor North Tower	AACT Members' Reception and FAACT Induction Ceremony <i>Moderator: Robert Palmer PhD, AACT President</i>
7:30 pm- 10:00pm Offsite Cactus Club	AAPCC SPI Meet & Greet Reception

Rooms	7:00 am	7:30 am	8:00 am	8:30 am	9:00 am	9:30 am	10:00 am	10:30 am	11:00 am	11:30 am	12:00 pm	12:30 pm	1:00 pm	1:30 pm	2:00 pm	2:30 pm	3:00 pm	3:30 pm	4:00 pm	4:30 pm	5:00 pm	5:30 pm	6:00 pm	6:30 pm	7:00 pm	7:30 pm	8:00 pm	8:30 pm	9:00 pm	9:30 pm	10:00 pm															
North Tower Lower Lobby	AACT Pre-Symposium Registration												NACCT Main Congress Registration																																	
Junior Ballroom 3rd Floor North Tower			AACT Pre-Symposium: Cardiotoxins An in-depth look at the Pathophysiology, Presentation, and Management of Heart Poisoning												ACMT Medical Toxicology: 19th Annual Clinical Pathologic Competition (CPC)																															
Pavilion Ballroom 3rd Floor South Tower													Set-Up - Exhibits/Poster Session I - Abstracts # 29-114																																	
Port Hardy 4th Floor North Tower			**ACMT Board Meeting**																		AAPCC Surveillance Team				AAPCC NPDS Updates																					
Finback 3rd Floor South Tower										**AAPCC Board Meeting** (Part 1)															CAPCC Business Meeting																					
Orca 3rd Floor South Tower			**ABAT Board Meeting (Part 2)**																				PEC Open Meeting		PEC Steering Committee																					
Beluga 3rd Floor South Tower			ABAT Exam (Part 2)																		PEC Meet & Greet																									
Port McNeill 4th Floor North Tower																										AACT Business & Membership Meeting		AACT Member Reception and FAACT Induction Ceremony																		
Parksville 3rd Floor North Tower																		**AAPCC Accreditation Committee Meeting **																												
Port Alberni 4th Floor North Tower																		AAPCC SPI Committee Meeting																												
Galiano 4th Floor South Tower																					AAPCC Benchmarking /QA Meeting	AAPCC Truven Joint Coding Committee Meeting																								
Off Site Cactus Club																								AAPCC SPI Meet & Greet																						
		Color Key		Main Symposium		AAPCC		ACMT		AACT		ABAT		MISC									**Private**		PEC		AHLS																			
	** Denotes Restricted Attendance to members/invitees only **																																													
	Room Names Subject to Change																																													

Bold Face – indicates CE sessions
* Restricted to committee members *

Bold Face – indicates CE sessions
* Restricted to committee members *

Friday, October 13, 2017

Conference Schedule

7:00 am – 5:00 pm North Tower Lower Lobby	NACCT Main Congress Registration / Information
7:00 am – 8:00 am Grand Ballroom Foyer	Continental Breakfast
7:00 am – 8:00 am Finback 3 rd Floor South Tower	ACMT Forensic Section Meeting
7:00 am – 8:00 am Granville 4 th Floor South Tower	ACMT Women in Medical Toxicology Meeting
7:00 am – 8:00 am Port Hardy 4 th Floor North Tower	ACMT Position Statements & Guidelines Meeting
7:00 am – 8:00 am Port Alberni 4 th Floor North Tower	AAPCC Public Health Committee Meeting
8:00 am – 9:00 am Grand Ballroom	NACCT Keynote Presentation: Open Science: Lessons from the Open-Source Outbreak Moderator: Mark Kostic, MD Presenter: Jennifer Gardy, MD

- At the end of the session, the participant should be able to:
1. Understand the benefits and challenges of the open science approach, including real-time data collection and data-sharing
 2. Identify tools and platforms that can be used in facilitating open science research.

Friday, October 13, 2017 (continued)

Conference Schedule

9:00 am – 10:00 am Grand Ballroom	AAPCC Scientific Symposium: The Path to a Canadian Antidotes Registry Moderator: Mark Ryan, PharmD Presenter: Pierre André Dubé, BS Pharm
At the end of the session, the participant should be able to:	
<ol style="list-style-type: none">1. Describe the initiatives in Quebec and Nova Scotia to standardize antidote stockpiles in hospitals providing emergency care.2. Discuss the advantages of a Canadian Antidotes Registry.	
9:00 am – 10:00 am Junior Ballroom AB 3 rd Floor	AACT Tox History Section Symposium Moderator: Anna Maria Arroyo Plasencia, MD Presentations: Toxicities, both Real and Imagined, Associated with the Development and Deployment of Polio Vaccines Sharon Ternullo, BS Pharm, PharmD The CRC: The Past, Present and Future Milton Tenenbein, MD

- At the end of the session, the participant should be able to:
1. Identify the adverse effects that have been attributed to both inactivated and live polio vaccines during their development, introduction, and subsequent clinic.
 2. Identify adverse effects detected during the 40s and 50s during early attempts to prevent polio that are relevant to drug development today.
 3. Discuss the history of the research and development of the Children Resistant Closure (CRC).
 4. Discuss the effectiveness of the CRC.

9:00 am – 4:00 pm Pavilion Ballroom 3 rd Floor	Exhibits
9:00 am – 4:00 pm Pavilion Ballroom 3 rd Floor	Poster Session I - Abstracts # 29-114

Friday, October 13, 2017 (continued) Conference Schedule

9:00 am – 5:00 pm Grand Ballroom Foyer 2nd Floor	toxiCall® Training
10:00 am – 11:00 am Pavilion Ballroom 3rd Floor	Authors with Posters - Abstracts # 29-114
11:00 am – 12:00 pm Grand Ballroom AB	AACT Acute and Intensive Care Symposium Moderators: <i>Jenny Lu, MD</i> <i>Bryan Hayes, PharmD</i> Presenters: <i>Nicklaus Brandehoff, MD</i> <i>Jeffrey Lai, MD</i>

At the end of the session, the participant should be able to:

1. Discuss the risk and benefits of ECMO in NSAID ingestion.
2. Discuss the risk large NSAID ingestions.
3. Describe the pathophysiology and clinical course of acute copper toxicity.
4. Understand the rationale for chelation therapy and supportive measures for acute copper poisoning.

11:00 am – 11:30 am Grand Ballroom CD	Lightening Cases: Abstracts #17-20: Moderator: <i>John Devlin, MD</i>
--	--

17 Eye See an EpiPen®: Complications from a Pediatric Ocular Epinephrine Injection, *Theresa Kim, MD*

18 Too Much Milkshake: Acute Chylous Ascites Following Intralipid Treatment for Flecainide Overdose, *Michael Butterfield, MD*

19 Two cases of ventricular dysrhythmias from aconitine poisoning, *Craig Smollin, MD*

20 Massive Dosing Error of Iron Dextran in a Newborn, *Jillian Theobald, MD, PhD*

Friday, October 13, 2017 (continued) Conference Schedule

At the end of the session, the participant should be able to:

1. To describe potential complications and outcomes after injection of epinephrine into the eye.
2. Recognize complications related to intralipid use.
3. Recognize the role of intralipid in treating acute poisonings.
4. Understand the pathophysiology and cardiovascular complications associated with ingestion of aconite.
5. Understand potential sources of aconite exposure from Traditional Chinese medicines.
6. Identify the adverse events related to an iron dextran overdose.
7. Recognize the dangers of giving deferoxamine for an iron dextran overdose.

11:00 am - 12:00 pm Junior Ballroom AB 3rd Floor	AAPCC Veterinary Symposium: Tasty and Toxic? Species Difference (Human and Veterinary) in Food Toxicology Moderators: <i>Tina Wismer, DVM</i> <i>Jan Scaglione, PharmD</i> Presenters: <i>Ahna Brutlag, DVM</i> <i>Laura Stern, DVM, ABVT</i>
--	--

At the end of the session, the participant should be able to:

1. Identify and understand key toxicological differences regarding mycological food borne illness between dogs and humans.
2. Identify and understand key toxicological differences regarding xylitol between dogs and humans.

11:00 am – 12:30 pm Junior Ballroom D 3rd Floor	PEC: Health Promotion Exploring Theories and Models that Relate to Health Behavior Change Moderator: <i>Gayle Finkelstein, RN</i> Presenter: <i>Anne-Marie Nicol, PhD</i>
---	--

At the end of the session, the participant should be able to:

1. Describe theories of health promotion.
2. Use a case study to illustrate how behavior change requires support across a wide range of variables.

Friday, October 13, 2017 (continued)Conference Schedule

11:00 am – 12:00 pm Granville 4 th Floor South Tower	AAPCC Government Affairs Committee Meeting
12:00 pm – 1:30 pm Finback 3 rd Floor South Tower	*Informa Editorial Board Meeting and Luncheon*
12:00 pm – 1:30 pm Port Alberni 4 th Floor North Tower	*AHLS Board Meeting*
12:30 pm – 1:30 pm	Lunch on Your Own
12:30 pm – 1:30 pm Orca 3 rd Floor South Tower	*Tox Collaborative- Activated Charcoal Project*
12:30 pm – 1:30 pm Granville 4 th Floor South Tower	*JMT Editorial Board Meeting*
12:30 pm – 1:30 pm Port Hardy 4 th Floor North Tower	ACMT Education Committee Meeting
1:30 pm – 3:15 pm Junior Ballroom D 3 rd Floor North Tower	PEC: Opioid Epidemic & Harm Reduction Moderator: Gayle Finkelstein, RN Presenters: Darwin Fisher, MS Bill Spearn, BA Jane Buxton, MBBS, MHSc Roy Purssell, MD

Friday, October 13, 2017 (continued)Conference Schedule

At the end of the session, the participant should be able to:	
<div>1. Understand the harm reduction and community engagement in response to the current crisis.</div> <div>2. Identify prevention strategies to combat risky behaviors related to opioid use.</div> <div>3. Increase awareness of the harm reduction approach to substance abuse and injury prevention.</div>	
1:30 pm – 3:30 pm Grand Ballroom AB	Platform Session I: Abstracts #1-8 Moderators: Darren Roberts, MBBS Mark Kostic, MD
#1 Effect of methylene blue on mortality in a porcine model of amlodipine toxicity, Jenna LeRoy, MD	
#2 A regional poison control center’s role in the public health response to multiple harmful algal blooms, Kaitlyn Brown, PharmD	
#3 Efficacy of intramuscular cobinamide in a swine model of severe hydrogen sulfide poisoning: a prospective trial, Vikhyat Bebarta, MD	
#4 Graft failure rates of organs transplanted from poisoned patients compared to other causes, Neeraj Chhabra, MD	
#5 Passive poison center exposure identification using the electronic medical record, Michael Lynch, MD	
#6 Early FabAV treatment improves time to full limb function recovery in patients with copperhead envenomation, Victoria Anderson	
#7 A randomized trial of intramuscular olanzapine versus oral clonidine for symptomatic treatment of opioid withdrawal in the emergency department, Lauren Klein, MD	
#8 A prospective study of the QTc prolonging effect of intravenous ondansetron administered to children with gastroenteritis, RJ Hoffman, MD	

At the end of the session, the participant should be able to:

1. Understand the mechanism of amlodipine toxicity and describe potential treatment options based on mechanism.
2. Describe the role poison control centers have in responding to public health concerns associated with harmful algal blooms.
3. Discuss the causes of hydrogen sulfide toxicity.
4. Discuss the role of cobinamide in sulfide poisoning.
5. Compare and contrast graft failure rates for organ procured from poisoned patients compared to other causes of death.
6. Describe the process and results from one poison center's experience using the electronic medical record to identify, document, and follow poison exposure cases.
7. Identify potential areas for improved data collection by poison centers.
8. Understand how time to treatment with FabAV affected recovery in patients with copperhead envenomation.
9. Discuss the comparative efficacy of olanzapine versus clonidine in the treatment of symptomatic opioid withdrawal.
10. Discuss the comparative safety concerns of olanzapine versus clonidine in the treatment of symptomatic opioid withdrawal.
11. Understand appropriate methods for evaluation of QT prolonging effects of medications.
12. Know the likely effect of ondansetron on QTc in children.

3:15 pm – 3:30 pm

Junior Ballroom D

3rd Floor North Tower

PEC Updates

3:30 pm – 3:45 pm

Pavilion Ballroom

3rd Floor South Tower

Refreshment Break

Sponsored by BTG International Inc.

3:45 pm – 4:45 pm

Junior Ballroom D

3rd Floor North Tower

PEC: The Art of the Perfect Social Media Post and How to Analyze Its Data

Moderator: Carissa McBurney, MPA

Presenter: Rebecca Coleman, BA/BE

At the end of the session, the participant should be able to:

1. Understand the mechanics of what makes a good social media post.
2. Understand how to tell if that post was successful or not.

3:45 pm – 5:15 pm

Grand Ballroom AB

AACT Pediatrics SIG & ACMT Addiction Medicine Symposium: The Impact of the Opioid Crisis on Children and Adolescents

Moderator: Katie O'Donnell, MD

Presenters: Diane Calello, MD

JoAn Laes, MD

Timothy Weigand, MD

Christine Murphy, MD

At the end of the session the participant should be able to:

1. Discuss the impact of the opioid epidemic in terms of the increase in pediatric opioid poisoning.
2. Formulate preventive action to mitigate risk to children living in at-risk environments for opioid poisoning.
3. Describe the pharmacotherapy options available for opioid use disorder in adolescents <18 yo.
4. Discuss the indications and approval for treatment of adolescents <18 yo with each medication.

3:45 pm – 4:45 pm

Grand Ballroom CD

AACT Toxicology Newshour Lecture: Recent Chemical Warfare (Cholinesterase Inhibitors) Attacks in Syria

Moderator: Nima Majlesi, DO

Presenters: Vikhyat Bebarta, MD

Mark Kirk, MD

At the end of the session the participant should be able to:

1. Discuss the events in Syria.
2. Discuss current tox and chemical events in the world.
3. Implement ways to leverage the role of a medical toxicologist in education of government agencies regarding large-scale chemical incidents.
4. Apply key findings from recent DHS work to help communities more effectively respond to large-scale chemical incidents.

Conference Schedule

3:45 pm – 4:45 pm
Junior Ballroom AB
3rd Floor North Tower

AACT Radiation Section Symposium: Acute Radiation Syndrome Update
Moderator: Arthur Chang, MD
Presenters: Stephen Borron, MD
Adam Pomerleau, MD

At the end of the session the participant should be able to:

1. Describe methods for assessment of acute radiation syndrome.
2. Identify radiation countermeasures and indications for their use.
3. Compare and contrast the use of filgrastim, peg-filgrastim, and sargramostim in the treatment of acute radiation syndrome.

3:45 pm – 4:45 pm
Junior Ballroom C
3rd Floor North Tower

SPI Best Practices Symposium: *Poison Center Perspectives on the Opioid Crisis*
Moderator: Jamie Nisbet, RN
Presenters: Jamie Nisbet, RN
Debra Kent, BA, PharmD

At the end of the session the participant should be able to:

1. Recognize significant health care/treatment changes that have occurred in a specific area (U.S. and Canada) as a result of increases in opiate overdoses.
2. Indicate ways that poison centers can aid communities, health care professionals, and first responders when dealing with opiate abuse/treatment.
3. Recognize harm reduction strategies that have been implemented in BC and Canada as a response to the opioid crisis.
4. Describe how surveillance of poison center data can contribute to understanding of opioid crisis.

4:00 pm – 4:30 pm Posters Session I Tear Down – Abstracts # 29-114
Pavilion Ballroom
3rd Floor South Tower

4:45 pm – 5:45 pm AAPCC Town Hall Meeting
Junior Ballroom AB
3rd Floor North Tower

Friday, October 13, 2017 (continued)

Conference Schedule

5:00 pm – 6:00 pm Poster Session II Set Up - Abstracts # 115-200
Pavilion Ballroom
3rd Floor South Tower

5:30 pm – 6:30 pm NACCT Opening Reception
Grand Ballroom Foyer

6:30 pm – 8:00 pm AAPCC Awards/Quiz Bowl
Grand Ballroom AB *Moderator: Prashant Joshi, MD*

6:30 pm – 8:00 pm ABAT Business Meeting
Junior Ballroom AB
3rd Floor North Tower

8:00 pm – 9:00 pm ABAT Members' Reception
Junior Ballroom C
3rd Floor North Tower

8:000 pm – 10:00 pm * NACCT Sponsors and Friends Dinner *
Offsite

[illegible]

Bold Face – indicates CE sessions
* Restricted to committee members *

Bold Face – indicates CE sessions
* Restricted to committee members *

Saturday, October 14, 2017

Conference Schedule

6:30 am – 7:30 am Junior Ballroom A 3 rd Floor North Tower	ACMT Medication Management Section Meeting
6:30 am – 7:30 am Junior Ballroom B 3 rd Floor North Tower	ACMT International Committee Meeting
6:30 am – 7:30 am Port McNeil 4 th Floor North Tower	ACMT ASM Planning Committee Meeting
6:30 am – 7:30 am Port Alberni 4 th Floor North Tower	ACMT Public Affairs Committee Meeting
7:00 am – 5:00 pm North Tower Lower Lobby	NACCT Main Congress Registration / Information
7:00 am – 8:00 am Grand Ballroom Foyer	Continental Breakfast
7:30 am – 8:30 am Grand Ballroom 2 nd Floor	AACT Career Achievement Award Symposium: Moderator: Robert Palmer, PhD, AACT President Presenter: Richard Dart, MD, PhD

At the end of the session, the participant should be able to:

- 1. Describe the role of poison centers in the opioid abuse epidemic.
- 2. Identify the challenges facing poison centers.

Saturday, October 14, 2017 (continued)

Conference Schedule

8:30 am – 10:00 am Junior Ballroom D 3 rd Floor North Tower	PEC: Marijuana: The Token of the Town Moderator: Kristen Wenger, M.T. Presenters: Robert S. Hoffman, MD George Sam Wang, MD Shane Holmquist, MA
8:30 am – 10:00 am Grand Ballroom	ACMT Scientific Symposium: Out of the Starting Gate: Medical Toxicology Research Study Design, Funding, and Patient Consent Moderators: Christina Hantsch Bardsley, MD Presenters: Jeffrey Brent, MD, PhD Peter Chai, MD, MMS Jon B. Cole, MD

At the end of the session, the participant should be able to:

- 1. Characterize the research that supports or refutes medical benefits of marijuana.
- 2. Discuss the differences between marijuana and mixtures of some of its active ingredients.
- 3. Understand the evolution of medical marijuana in Canada through court cases & number of licenses.
- 4. Popular cannabis consumption methods and derivatives.

At the end of the session, the participant should be able to:

- 1. Describe what an observational study is.
- 2. Describe what an interventional study is.
- 3. Understand state of the art technological advances in management of substance abuse and the poisoned patient.
- 4. Discuss how to think critically about how technology can be used to react to episodes of drug or substance use.
- 5. Define the difference between Waiver and Exception from Informed Consent.
- 6. Develop an approach to the implementation of research on patients without obtaining consent.

Saturday, October 14, 2017 (continued) Conference Schedule

8:30 am – 10:00 am
Junior Ballroom C
3rd Floor North Tower

SPI Roundtable Symposium
Moderator: LaDonna Gaines, BSN,MPH,RN

Presentations:

Don't mess with the zofran!
Justin Carter, PharmD

Bypass Bypassed? Rethinking a Fatal Acetaminophen Regiment
Dionna Douglas, MD

Panelists: Shan Yin, MD, MPH
Alexander Garrard, PharmD

At the end of the session, the participant should be able to:

1. Recognize potential toxicity that may be seen after accidental overdose of ondansetron in a child.
2. Select interventions used in management of ondansetron toxicity.
3. Understand the role of a complete medical history, including procedures such as gastric bypass.
4. Consider a lower threshold for chronic acetaminophen therapy in those with a history of gastric bypass.

9:00 am – 4:00 pm
Pavilion Ballroom
3rd Floor South Tower

Exhibits

9:00 am – 4:00 pm
Pavilion Ballroom
3rd Floor South Tower

Poster Session II - Abstracts #115 - 200

9:00 am – 5:00 pm
Grand Ballroom Foyer

toxiCall® Training

9:00 am – 10:00 am
Junior Ballroom A
3rd Floor North Tower

AACT Pediatric Section Meeting

Saturday, October 14, 2017 (continued) Conference Schedule

9:00am – 10:00 am
Junior Ballroom B
3rd Floor North Tower

AACT Herbs & Dietary Supplements Section Meeting

10:00 am – 11:00 am
Pavilion Ballroom
3rd Floor South Tower

Authors with Posters – Abstracts # 115 - 200

10:00 am – 11:00 am
Port McNeil
4th Floor North Tower

NACCT/ACMT Leadership Meeting

11:00 am – 12:30 pm
Grand Ballroom AB

APAMT Scientific Symposium: Prescription Medicine Misuse Outside North America
Moderator: Paul Dargan, MD

Presentations:

Prescription medicine misuse outside of North America: An Asian perspective
Wui Ling Chan, MMED (EM)

Prescription medicine misuse outside of North America: An European perspective
David Wood MD

Prescription medicine misuse outside of North America: An Australian perspective
Rose Cairns, BS Pharm, PhD

At the end of the session, the participant should be able to:

1. State reasons why prescription medicine misuse is gaining popularity in Asia.
2. List the types of commonly misused drugs in Singapore.
3. Understand the extent of prescription medication misuse in Europe.
4. Describe the classes of prescription medicines associated with acute harms in Europe.
5. Describe trends in prescription medicine misuse in Australia.
6. Describe potential strategies for preventing prescription medicine misuse.

Bold Face – indicates CE sessions
* Restricted to committee members *

Bold Face – indicates CE sessions
* Restricted to committee members *

Saturday, October 14, 2017 (continued) Conference Schedule

11:00 am – 12:00 pm **PEC: Epidemiology for Non-Epidemiologists: Using Poison Center Data**
Junior Ballroom D
3rd Floor North Tower
Moderator: Kristin Wenger, M.T.
Presenter: Wendy Stephan, MPH, PhD Candidate

At the end of the session, the participant should be able to:

- 1. Identify sources of poison center data for public access and AAPCC member access.
- 2. Explain differences in terms and codes used in poison center charts and studies.

11:00 am – 11:30 am **Lightening Orals Abstracts # 21 – 24**
Grand Ballroom CD
Moderator: Jon B. Cole, MD

21 The Characterization of Carfentanil Sales on a Major Darknet Cryptomarket,
Michael Marlin, MD

22 How Sweet It Is: Sodium Glucose Co-transporter 2 Inhibitor Ingestions Reported to U.S. Poison Center, *Ronald Kirschner, MD*

23 Multi-center analysis of self-reported drug and ethanol use in sexual assault patients taken prior to, or during an assault, *Jennie Buchanan, MD*

#24 Safety and efficacy of idarucizumab in clinical practice, *Josh J. Wang, MD*

At the end of the session, the participant should be able to:

- 1. Understand the basics of accessing the darknet.
- 2. Understand best practices for obtaining useful data and metrics.
- 3. Discuss clinical features and medical outcome in SGLT2 inhibitor exposures reported to poison centers.
- 4. Describe settings in which SGLT2 inhibitors have been associated with hypoglycemia.
- 5. Understand ethanol continues to be the most common agent involved in sexual assault self-reporting over time.
- 6. List the most common agents self-reported over time involved in sexual assault.
- 7. Understand the clinical and biochemical impact of idarucizumab on real patients at a single multi-hospital health network.

Saturday, October 14, 2017 (continued) Conference Schedule

11:30 am – 12:30 pm **AACT Debate: Benzodiazepines or Antipsychotics for the Acutely Violent, Intoxicated Patient**
Grand Ballroom CD
Moderator: Jon B. Cole, MD
Presenters: Jon B. Cole, MD
Cynthia Aaron, MD

At the end of the session, the participant should be able to:

- 1. Discuss the risks and benefits of using either antipsychotics or benzodiazepines in this patient population.
- 2. Compare and contrast the QTc risks of various antipsychotics.
- 3. Decide which class of drugs would be most appropriate to treat the acutely violent and/or intoxicated patient.

12:00 pm – 12:15 pm PEC Updates
Junior Ballroom D
3rd Floor North Tower

12:30 pm – 1:30 pm Lunch on your Own

12:30 pm – 1:30 pm *AAPCC Committee Chairs & Fatality Review Luncheon*
Junior Ballroom B
3rd Floor North Tower

12:30 pm – 1:30 pm ACMT PEHSU Town Hall
Junior Ballroom A
3rd Floor North Tower

12:30 am – 1:30 pm ACMT Practice Committee Meeting
Port McNeil
4th Floor North Tower

12:30 pm – 1:30 pm *AACT Scientific Review Committee Section Meeting *
Port Hardy
4th Floor North Tower

12:30 pm – 1:30 pm AACT Geriatric Section Meeting
Port Alberni
4th Floor North Tower

Bold Face – indicates CE sessions
* Restricted to committee members *

Bold Face – indicates CE sessions
* Restricted to committee members *

12:30 pm – 1:30 pm
Junior Ballroom C
3rd Floor South Tower

AACT Fellows – in – Training and Leaders’ Luncheon

1:30 pm – 2:30 pm
Grand Ballroom AB

Platform Session II: Abstracts #9 - 12
Moderators: Bruno Megarbane, MD, PhD
James Mowry, PharmD

9. When Lipid Rescue is not the Magic Bullet, Susan Smolinske, PharmD
10. Prognostic Factors for Patients with Hemolysis from Brown Recluse Spider Envenomation, Justin Loden, PharmD
11. Pediatric Sedation Weaning Protocol Decreases Prescriptions for High Risk Opioids, Katherine O’Donnell, MD
- 12.Assessment of simulated naloxone administration by community members, William Eggleston, PharmD

At the end of the session, the participant should be able to:

1. Understand factors that are present when IV lipid emulsion therapy does not prevent death in poisoning overdoses.
2. Name the most common substances where IV lipid emulsion and used in fatal cases.
3. Identify which symptoms and laboratory abnormalities are predictive of hemolysis development after brown recluse spider envenomation.
4. Describe the components of a successful pediatric sedation weaning protocol.
5. Compare the ease of use of spray, atomized, and intramuscular naloxone when administered by community members.

1:30 pm – 2:30 pm
Grand Ballroom CD

AACT Occupational and Environmental Toxicology Section Symposium: Remediation and Sequelae of Oil Pipeline Spills
Moderator: David Vearrier, MD, MPH
Presenters: David Vearrier, MD, MPH
Michael Holland, MD

At the end of the session, the participant should be able to:

1. Understand the environmental consequences of oil pipelines spills.
2. Describe remediation techniques and endpoints for soil, surface water, and ground water.
3. Discuss potential for adverse human health effects from oil spills.
4. Describe potential health effects to oil spill cleanup workers.

1:30 pm – 2:30 pm
Junior Ballroom D
3rd Floor North Tower

PEC AAPCC Updates
Moderator: Deidre M George Davis
Presenter: Krista Osterthaler, MPH

At the end of the session, the participant should be able to:

1. Describe AAPCC's initiatives aimed at raising national awareness of poison control centers.
2. Describe AAPCC's initiatives aimed at preventing unintentional poisonings.

2:30 pm – 3:30 pm
Grand Ballroom AB

ACMT Practice Symposium: Groups, Tweets, and Friend Requests: Modern Marketing of Your Toxicology Expertise
Moderators: Spencer Greene, MD, MS
Presenters: Spencer Greene, MD, MS
Christopher H. Howard, JD

At the end of the session, the participant should be able to:

1. Review the use of various social media platforms to promote their toxicological expertise.
2. Discuss common pitfalls of using social media to promote a business.
3. Avoid common pitfalls of using social media to promote a business.

2:30 – 3:30 pm
Grand Ballroom CD

AACT Herbals Section Symposium: Green Tea, the Good and the Ugly
Moderator: Michael Hodgmann, MD

Presentations:

Therapeutic properties of green tea catechins against environmental insults
Chwan-Li (Leslie) Shen, PhD

Hepatotoxicity of Green Tea Hepatotoxicity of Green Tea
Raymond SM Wong, MD

At the end of the session, the participant should be able to:

- 1. Discuss the five most common environmental toxins and toxicants to humans: pesticides, smoke, mycotoxins, PCB, and arsenic.
- 2. Understand how green tea protect humans from these environmental toxins and toxicants.
- 3. Describe a proposed mechanism of green tea liver injury.
- 4. Describe epidemiology green tea hepatotoxicity.

2:30 pm – 3:30 pm ***PEC: Designing & Using Program Evaluations***
Junior Ballroom D ***Moderator: Becky Rozier, MSN, RN***
3rd Floor North Tower ***Presenter: Gail Banach, MS, MEd***

At the end of the session, the participant should be able to:

- 1. Identify the key components of a learning objective.
- 2. Select an example of process evaluation.

2:30 pm – 3:00 pm **AACT WMD/Radiation Section Meeting**
Junior Ballroom A
3rd Floor North Tower

3:30pm – 3:45 pm **Refreshment Break**
Pavilion Ballroom
3rd Floor South Tower

3:45 pm – 4:45 pm ***ABAT Scientific Symposium: The Dark Web: Cyberspace***
Grand Ballroom AB ***Marketplace***
 Moderator: Alfred Aleguas, PharmD
 Presenters: Shawn Varney, MD
 Kathi Meier, PharmD

At the end of the session, the participant should be able to:

- 1. Describe the history, development, and influence of the Dark Web and its toxicological impact on the world today.

- 2. Understand general cannabinoid pharmacology and toxicology.
- 3. Discuss the toxic and therapeutic effects of the natural and synthetic cannabinoid products that have been developed over the last 50 years.

3:45 pm – 4:45 pm ***ACMT Fellows - in - Training Visiting Professor: The***
Grand Ballroom CD ***Advantage of Developing a Niche for Your Medical***
 Toxicology Career
 Moderator: Christina Hantsch Bardsley, MD
 Presenter: Christopher Hoyte, MD

At the end of the session, the participant should be able to:

- 1. Discussing the opportunities that niches provide for a career.
- 2. How to discover a niche.

3:45 pm – 4:45 pm ***PEC Symposium: Toxicology 101 for Public Educators:***
Junior Ballroom D ***Common Pediatric Exposures***
3rd Floor North Tower ***Moderator: Becky Rozier, MSN, RN***

Presentations:

Small Doses, Big Problems
Becky Rozier, MSN, RN

Hazardous Baby Products
Alyssa Guttenberg, RN, ND

Toxicology 101 for Public Educators: Common Pediatric
Exposures
Tammy Noble, RN

At the end of the session, the participant should be able to:

- 1. Identify three household products that can be toxic to toddlers in small doses.
- 2. Identify various baby products that can lead to toxicity if used incorrectly or ingested by an infant or child.
- 3. List sources of lead and methods of preventing lead poisoning.

Saturday, October 14, 2017 (continued)

Conference Schedule

3:45 pm – 4:45 pm
Junior Ballroom A
3rd Floor North Tower

AACT Occupational & Environmental Section Meeting

3:45 pm – 4:45 pm
Port Hardy
4th Floor North Tower

AACT Envenomation's Section Meeting

4:00 pm – 4:30 pm
Pavilion Ballroom
3rd Floor South Tower

Poster Session II Tear Down – Abstracts # 115 - 200

4:30 pm – 5:30 pm
Pavilion Ballroom
3rd Floor South Tower

Poster Session III Set Up - Abstracts # 201 - 286

4:45 pm – 5:45 pm
Junior Ballroom C
3rd Floor North Tower

AAPCC Managing Directors Meeting

4:45 pm – 5:45 pm
Junior Ballroom B
3rd Floor North Tower

AAPCC Medical Directors

4:45 pm – 6:15 pm
Port McNeil
4th Floor North Tower

ACMT ToxIC Network Meeting

6:30 pm – 10:30 pm
Offsite

Science World at Telus World of Science Tour & Dinner
(Purchased ticket required)
(Coach boarding begins @ 5:45 PM South Tower,
Hotel Entrance)

Rooms	6:30 am	7:00 am	7:30 7:45 AM	8:00 am	8:30 am	9:00 am	9:30 am	10:00 am	10:30 am	11:00 am	11:30 am	11:45 AM	12:00 PM	12:30 pm	12:45 PM	1:00 pm	1:30 pm	2:00 pm	2:30 pm	2:45 PM	3:00 pm	3:30 pm	3:45 PM	4:00 pm	4:30 pm	4:45 PM	5:00 pm	5:30 pm	6:00 pm	6:30 pm	7:00 pm	7:30 pm	8:00 pm	8:30 pm	9:00 pm					
North Tower Lower Lobby	Main Congress Registration/Information																																Total Downtime - Poster Session III - Abstracts # 201-286							
Pavilion Ballroom 3rd Floor South Tower																																								
Pavilion Ballroom 3rd Floor South Tower																																								
Grand Ballroom																																								
Grand Ballroom AB																																								
Grand Ballroom CD																																								
Junior Ballroom D 3rd Floor North Tower																																								
Post Meets 4th Floor North Tower																																								
Junior Ballroom C 3rd Floor North Tower																																								
Junior Ballroom A 3rd Floor North Tower																																								
Junior Ballroom B 3rd Floor North Tower																																								
Post Meets 4th Floor North Tower																																								
										</																														

Bold Face – indicates CE sessions
* Restricted to committee members *

Bold Face – indicates CE sessions
* Restricted to committee members *

Sunday, October 15, 2017

Conference Schedule

6:30 am – 7:30 am Port Hardy 4 th Floor North Tower	ACMT Fellowship Directors Committee
6:30 am – 7:30 am Junior Ballroom B 3 rd Floor North Tower	ACMT Recent Graduates Section Meeting
7:00 am - 4:00 pm North Tower Lower Lobby 2 nd Floor	NAACT Main Congress Registration / Information
7:00 am – 8:00 am Grand Ballroom Foyer 2 nd Floor	Continental Breakfast
7:30 am - 8:30 am Grand Ballroom	<u>AACT Scientific Symposium: Toxicology of Other Alcohols</u> <i>Moderator: Kennon Heard, MD</i> <i>Presenter: Kenneth McMartin, PhD</i>
At the end of the session, the participant should be able to:	
<div>1. Describe the mechanisms of toxicity of glycol ethers as related to applicable therapies.</div> <div>2. Discuss the role of diglycolic acid in the toxic effects of diethylene glycol.</div>	
7:30 am – 8:30 am Junior Ballroom A 3 rd Floor North Tower	AAPCC Toxicall Users Group
7:30 am – 8:30 am Junior Ballroom B 3 rd Floor North Tower	AAPCC ToxSentry Data Group

Sunday, October 15, 2017 (continued)

Conference Schedule

7:45 am – 8:30 am Junior Ballroom D 3 rd Floor North Tower	<u>PEC: HRSA Updates</u> <i>Moderator: Deirdre M George Davis, MPH</i> <i>Presenter: Jackie Kennedy, CDR, USPHS</i>
At the end of the session, the participant should be able to:	
<div>1. Identify HRSA's current projects related to the poison center promotion.</div> <div>2. Recommend ways HRSA can support poison prevention programs.</div>	
8:30 am – 9:30 am Grand Ballroom	<u>CAPCC Scientific Symposium: Public Health Emergency: The British Columbia Experience with the Opioid Crisis</u> <i>Moderator: Margaret Thompson, MD</i> <i>Presenter: Jane Buxton, MD</i>
At the end of the session, the participant should be able to:	
<div>1. Define a public health emergency.</div> <div>2. List the interventions specific to the opioid crisis in BC commenting on their successes and challenges.</div> <div>3. List 3 advantages of engaging people with lived experience in providing overdose prevention services</div>	
8:30 am – 9:30 am Junior Ballroom D 3 rd Floor North Tower	<u>PEC: Marketing: Why Branding is Important</u> <i>Moderator: Deirdre M George Davis, MPH</i>
<i>Presentations:</i>	
<i>Marketing: Why Branding is Important</i> <i>Carissa McBurney, MPA</i>	
<i>Brand Readiness: The Questions to Ask Before You Begin Marketing</i> <i>Alexa Steverson, MA</i>	

At the end of the session, the participant should be able to:

1. Explain what the term marketing truly means.
2. Identify and describe branding techniques and benefits.
3. Identify at least one key question that should be asked as a precursor to marketing efforts.
4. Assess the organization's readiness level for strategic branding.

8:30 am – 9:30 am
Port Hardy
4th Floor North Tower

AACT Finance/Sponsorship Meeting

8:30 am – 9:30 am
Junior Ballroom C
3rd Floor North Tower

SPI Clinical Practice Symposium: *The Cost of Treating the Poisoned Patient*
Moderator: Jamie Nisbet, RN
Presenters: Jeanna Marraffa, PharmD
Keith Boesen, PharmD,

At the end of the session, the participant should be able to:

1. Identify factors that drive the cost of antidotes.
2. Recognize the costs associated with the use of specific antidotes and treatments used in toxicology.
3. Recognize the costs associated with the use of specific antidotes and treatments used in toxicology.
4. Determine possible health care costs of self-referral patients who have the potential to be monitored at home rather than in the hospital setting.

9:00 am – 4:00 pm
Grand Foyer

toxiCall® Training

9:30 am – 3:30 pm
Pavilion Ballroom
3rd Floor South Tower

Exhibits

9:30 am – 4:00 pm
Pavilion Ballroom
3rd Floor South Tower

Poster Session III - Abstracts # 201- 286

9:30 am – 10:30 am
Pavilion Ballroom
3rd Floor North Tower

Authors with Posters / Abstracts # 201 - 286

10:30 am – 12:00 pm
Grand Ballroom AB

EAPCCT Scientific Symposium: *Current Controversies in Pesticide Toxicology*
Moderator: Martin Wilks, MD, PhD

Presentations:

Acute organophosphorus pesticide poisoning – are there clinically relevant differences in diagnosis and treatment in comparison to nerve agents
Horst Thiermann, MD

Pesticide exposure and neurodegenerative disease - is there a causal link?
Martin F. Wilks, MD, PhD

Neonicotinoid Insecticides: Safe for Humans, but Toxic to Bees?
J. Allister Vale, MD

At the end of the session, the participant should be able to:

Discuss substantial differences of single organophosphorus compounds acute toxicity.

Discuss facts that affect effectiveness of antidotal therapy in organophosphorus compound poisoning.

Understand the evidence for a causal relationship between exposure to specific pesticides and neurodegenerative disease.

Discuss new approaches to the integration of data to define key events in the pathway from exposure to adverse outcome.

Understand mechanistically why human neonicotinoid poisoning occurs.

Understand why neonicotinoids may impact bees.

10:30 am – 12:00 pm

Grand Ballroom CD

Lightening Orals Abstracts #25 - 28

Moderator: Mark Winter, PhD

#25 **Palatability of effervescent vs standard oral n-acetylcysteine: Is it worth all the fizz?** Ann Marie Guthrie, PharmD

#26 **Adjunct Ketamine Use in the Management of Severe Ethanol Withdrawal,** Anthony Pizon, MD

#27 **Physostigmine versus Standard Cares for Anticholinergic Toxicity: A Prospective Study of Efficacy and Adverse Events,** Sean Boley, MD

#28 **ReCAP2: Reducing Childhood Admissions to the PICU for Poisoning by Predicting Unnecessary PICU Admissions after Acute Ingestion,** Meral Patel, MD

At the end of the session, the participant should be able to:

1. Discuss barriers to treatment of acetaminophen overdose with n-acetylcysteine such as palatability.
2. Understand the role ketamine plays in the treatment of ethanol withdrawal.
3. Understand the pathophysiology of ethanol withdrawal.
4. Understand the risks and benefits of using physostigmine for anticholinergic toxicity.
5. To derive and validate clinical prediction models to objectively identify children at low risk of clinically significant intoxications for whom intensive care admission is unnecessary.

10:30 am – 11:30 am

Junior Ballroom D

3rd Floor North Tower

PEC: Tailored and Targeted Health Communication: Strategies for Enhancing Information Relevance for Children, for Adolescents, and for Senior Adults

Moderator: Stefanie Baines, MA

Presenters: Carissa McBurney, MPA

Lee Livermore, BAA

Kristin Wenger, M.T., BS

At the end of the session, the participant should be able to:

1. Introduce the unique learning challenges presented by three different populations: young children (preschool to elementary); adolescents; and senior adults.
2. Describe strategies and best practices for communicating poisoning prevention information to each of those audiences.
3. Understand and Develop education strategies for poison prevention topics relevant to adolescents.
4. Understand the differences in outreach education with adolescents' verses adults.
5. Develop strategies for communicating information to senior adults which will result in enhanced learning of the information.
6. List barriers that may prevent seniors from fully absorbing material in a presentation.

11:00 am – 12:00 pm

Grand Ballroom CD

AACT Forensics Section Symposium: Case Files for the Medical Examiners' Office

Moderator: Rama Rao, MD

Presentations:

Non-Therapeutic Drug Use, Mixed Message to the Public, Providers, Law Enforcement and Forensic Toxicologists
Rama Rao, MD

Errors in the postmortem toxicology literature
Robert Palmer, PhD

Sentinel Carfentanil Deaths in the Midwest
Travis Olives, MD

At the end of the session, the participant should be able to:

1. Understand some of the fundamental mistakes in the published postmortem toxicology
2. Literature leading to erroneous interpretation.
3. Discuss an interagency response to a novel opioid outbreak.
4. Discuss post-mortem carfentanil levels among an index group of decedents.

Sunday, October 15, 2017 (continued)Conference Schedule

11:30 am – 11:45 am Junior Ballroom D 3rd Floor North Tower	PEC Updates
11:45 am – 12:45 pm Junior Ballroom B 3rd Floor North Tower	PEC 2018 NACCT Planning Meeting
12:00 pm – 1:00 pm	Lunch on Your Own
12:00 pm – 1:00 pm Port McNeil 4th Floor South Tower	*Tox Collaborative – Prolonged QT Project*
12:00 pm – 1:00 pm Port Hardy 4th Floor North Tower	ACMT Addiction Medicine Section Meeting
12:00 pm – 1:00 pm Junior Ballroom C 3rd Floor North Tower	ACMT Government Section Meeting
12:00 pm – 1:00 pm Junior Ballroom B 3rd Floor North Tower	*Informa Senior Editorial Board Meeting*
1:00 pm – 2:00 pm Grand Ballroom AB	Platform Session III: Abstracts #13 - 16 Moderators: Mark Ryan, PharmD Michael Lynch, MD

#13 Treating valproic acid intoxication using conventional hemodialysis combined with protein binding displacers: An in-silico analysis, Vaibhav Maheshwari

#14 Retrospective assessment of desmopressin effect on hematoma expansion and safety in antiplatelet-treated patients with intracranial hemorrhage, Elizabeth Feldman, PharmD, Robert Seabury, PharmD

#15 Dosing Strategies of N-acetylcysteine for Acetaminophen Overdose in Patients Greater than 100 Kilograms. An Evaluation of Dosage capping, Regan Baum, PharmD

Sunday, October 15, 2017 (continued)Conference Schedule

#16 Is Silibinin Any Better Than Chicken Dung for Treating the Fulminant Hepatic Failure of Amatoxin Mushroom Poisoning? Results of the North American Open Label Prospective IND Clinical Trial, Todd Mitchell

At the end of the session, the participant should be able to:

1. Recognize and appreciate a new way of treating intoxication patients. Binding competition during dialysis can significantly improve dialysis efficacy.
2. Review the power of comprehensive mathematical models.
3. Assess the impact of DDAVP on hematoma expansion and its side effects in antiplatelet-treated patients with intracranial hemorrhage compared to no treatment.
4. Assess the impact of DDAVP's side effects in antiplatelet-treated patients with intracranial hemorrhage compared to no treatment.
5. Understand current evidence and rational guiding N-acetylcysteine dosing in patient's weighing greater than 100kg.
6. Describe potential benefits and drawbacks of dose capping.
7. Understand the role of IV Silibinin in the management of Amatoxin Mushroom Poisoning and why the drug has been associated with treatment failures.
8. Understand the toxicokinetics of Amatoxin Poisoning.

1:00 pm – 2:00 pm
Grand Ballroom CD
AACT Fellows – in – Training Brief Oral Presentations
Moderator: Kennon Heard, MD

Presentations:

The effect of caffeine on central apnea induced by organophosphate poisoning in an anesthetized rat model, Evan Bradley, MD, PhD

Cyclosporine as a novel treatment for amatoxin-containing mushroom poisoning
Emily Austin, MD

Unintentional pediatric exposures to antidementia medications reported to US poison control centers, Kaitlyn Brown, MD

Clinical presentations of alcohol naïve patients with very high blood alcohol concentrations, Lisa Moddemann, MD

Use of Topical Capsaicin Cream for the Treatment of Cannabinoid Hyperemesis Syndrome, Suraj Rajasimhan, PharmD

At the end of the session, the participant should be able to:

1. Understand the effects of caffeine on a basic science model of central apnea induced by organophosphate poisoning.

2. Describe the role of the OATP1B3 transporter protein in amatoxin poisoning.

3. Describe why cyclosporin may have a role in the treatment of amatoxin poisoning.

4. Describe unintentional pediatric exposures to antidementia medications.

5. Recognize the broad clinical presentations of alcohol intoxication in alcohol naive patients Identify how the demographic profile of juvenile and adult patients presenting in this cohort differ with very high blood alcohol concentrations.

6. Describe the common signs and symptoms of cannabinoid hyperemesis syndrome.

7. Explain the mechanism of action of capsaicin and its potential benefits in cannabinoid hyperemesis syndrome.

1:30 pm – 2:30 pm

Port McNeil

4th Floor North Tower

PEC: Swap and Share
Moderator: Stefanie Baines, MA
Presenter: Nikesha Yarbrough, BS

At the end of the session, the participant should be able to:

1. Share information about innovative and creative programs.

2. Compare poison prevention materials from a variety of poison centers.

2:00 pm – 2:30 pm

Grand Ballroom AB

AACT Environmental Tox: Health Risk Assessment with Emphasis on a Lead Mine in Indonesia
Moderator/Presenter: Scott Phillips, MD

At the end of the session, the participant should be able to:

1. Understand the general practice of health Risk assessment in toxicology.

2. Experience the scope of health risk assessment testing.

2:00 pm – 2:30 pm

Grand Ballroom CD

AACT Sports Tox Section Symposium: The Use of Performance Enhancing Drugs and Exercise Recovery in the Athlete
Moderator/Presenter: Christopher Hoyte, MD

At the end of the session, the participant should be able to:

1. Discuss interventions to increase muscle glycogen capacity

2. Understand the physiologic role muscle glycogen plays in recovery from stress.

2:30 pm – 2:45 pm

Pavilion Ballroom

3rd Floor South Tower

Refreshment Break

2:45 pm – 3:45 pm

Grand Ballroom AB

Toxicological Jeopardy for SPIs
Moderator: Edward Bottei, MD

At the end of the session, the participant should be able to:

1. Identify diagnostic clues to help recognize uncommon exposures.

2. List diagnostic criteria for certain common exposures of syndromes.

2:45 pm - 3:45 pm

Grand Ballroom CD

ACMT Fellows - in - Training Roundtable: Government Jobs and Opportunities for Medical Toxicologists
Moderator: Jeffrey Brent, MD, PhD
Presenters: Mark Kirk, MD
Keith Burkhart, MD
Richard Wang, DO

At the end of the session, the participant should be able to:

1. Discuss the pro of working as a medical toxicologist in government.

2. Discuss the cons of working as a medical toxicologist in government.

Sunday, October 15, 2017 (continued)

Conference Schedule

2:45 pm – 4:45 pm
Junior Ballroom D
3rd Floor North Tower

Medical Toxicology 2017 LLSA Article Review
Moderator: Kurt Kleinschmidt, MD
Presenters: Brandon Warrick, MD
Jakub Furmaga, MD
Kristin Domanski, MD
Brandon Wills, DO

At the end of the session, the participant should be able to:

1. State the situation where medical treatment would be done before decontamination.
2. Name a laboratory technique that can mitigate lipemia interference after lipid emulsion therapy.

2:45 pm – 3:45 pm
Port Hardy
4th Floor North Tower

ACMT Industry Section Meeting

2:45 pm – 3:45 pm
Junior Ballroom C
3rd Floor North Tower

ACMT Military Section Meeting

2:45 pm – 3:45 pm
Junior Ballroom A
3rd Floor North Tower

NACCT Partnership Meeting

3:45 pm – 4:30 pm
Pavilion Ballroom
3rd Floor South Tower

Poster Session III Tear Down – Abstracts # 201 - 286

[illegible]

Bold Face – indicates CE sessions
* Restricted to committee members *

Bold Face – indicates CE sessions
* Restricted to committee members *

7:30 am – 2:30 pm

AAPCC Board Meeting (Part 2)

Junior Ballroom AB

3rd Floor North Tower

Rooms	7:00 am	7:30 am	8:00 am	8:30 am	9:00 am	9:30 am	10:00 am	10:30 am	11:00 am	11:30 am	12:00 pm	12:30 pm	1:00 pm	1:30 pm	2:00 pm	2:30 pm	3:00 pm	3:30 pm	4:00 pm	4:30 pm	5:00 pm	5:30 pm	6:00 pm	6:30 pm	7:00 pm	7:30 pm	8:00 pm	8:30 pm	9:00 pm
Junior Ballroom AB 3rd Floor North Tower		AAPCC Board Meeting (Part 2)																											
		Color Key			Main Symposium		AAPCC			ACMT			AACT				ABAT			MISC			**Private**		AHLS				
	** Denotes Restricted Attendance to members/ invitees only **																												
	Room Names Subject to Change																												

Continuing Education

NORTH AMERICAN CONGRESS OF CLINICAL TOXICOLOGY 2017

SHERATON WALL CENTRE
VANCOUVER, BC
OCTOBER 11-15, 2017

CONTINUING EDUCATION CREDIT

Continuing education credits for pharmacists and physicians are awarded by the American Academy of Clinical Toxicology. Application for nursing credits has been submitted to the California Board of Nursing.

Requirements for Successful Completion

To successfully complete the requirements for Continuing Medical Education (CME) credit, Continuing Pharmaceutical Education (CPE) credit, or Continuing Education Contact Hours (Nursing), completes the following steps:

1. Submit the required Continuing Education Credit fee (\$200 for the Main Congress, \$80 for Pre-meeting Symposium).
2. Complete an online evaluation form for each session attended. Go to www.prolibraries.com/nacct/redeem and enter your Conference Code **NACCT17**, verify your attendance and create an account. If you previously set up an account, enter your username and password. Click on "Sessions Evaluations" and select the session(s) you need to evaluate. Also, complete the total "Conference Evaluation".
3. Your CE Certificate can be accessed and printed any time after you have completed the evaluation process by clicking on "CE Transcript" under "Your Account".
4. IMPORTANT: In order to obtain contact hours for the sessions you attended, you MUST complete the online evaluation process by **November 15, 2017**.

Objectives

- Review the pathophysiology and possible treatments of toxic alcohols other than ethanol, methanol, and ethylene glycol.
- Review the scientific evidence behind naloxone kit distribution programs.
- Discuss the cost of treating a poisoned patient, including the changing prices of antidotes.
- Develop an approach to incorporating various granulocyte colony stimulating factors into a treatment algorithm for acute radiation sickness.
- Explain the pharmacology of cannabinoid receptors and how they have affected the landscape of drugs of abuse in the 21st century.
- Develop a treatment algorithm for the acutely violent intoxicated patient that incorporates both benzodiazepines and antipsychotics.
- Describe antidote stocking in Canada and lessons learned that could be applied elsewhere.

NORTH AMERICAN CONGRESS OF CLINICAL TOXICOLOGY 2017

SHERATON WALL CENTRE
VANCOUVER, BC
OCTOBER 11-15, 2017

- List the consequences of oil pipeline spills.
- Identify toxins and their relative danger in humans versus animals.
- Compare and contrast prescription medicine misuse in North America versus Europe and Australasia.
- Discuss the impact of the opioid crisis on children and adolescents.
- Review health risk assessments in the context of an Indonesian lead mine.
- Discuss the current controversies in pesticide toxicology.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Education (ACCME) through the joint providership of American Academy of Clinical Toxicology (AACT), the American Association of Poison Control Centers (AAPCC) and the American College of Medical Toxicology (ACMT). AACT is accredited by the ACCME to provide continuing medical education for physicians.

The American Academy of Clinical Toxicology designates this live activity for a maximum of 38 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.



American Academy of Clinical Toxicology, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This program was designed in accordance with the Accreditation Council for Pharmacy Education's Accreditation Standards and the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education.

This Congress will have multiple ACPE Universal Program Numbers. Pharmacists can earn up to a maximum of 38 continuing education credit hours. Each pharmacist should claim only those hours of credit that he/she actually spent in the educational activity.

NORTH AMERICAN CONGRESS
OF CLINICAL TOXICOLOGY 2017

SHERATON WALL CENTRE
VANCOUVER, BC
OCTOBER 11-15, 2017

NORTH AMERICAN CONGRESS
OF CLINICAL TOXICOLOGY 2017

SHERATON WALL CENTRE
VANCOUVER, BC
OCTOBER 11-15, 2017

NACCT will be utilizing CPE Monitor for tracking and reporting of all ACPE-accredited continuing pharmacy education activities. Pharmacists are required to complete their e-profile at www.nabp.net to obtain their NABP e-Profile ID. Please remember that you will need to submit the NABP e-profile ID and birth date to receive credit at this year's meeting. **To obtain continuing education credit, evaluations must be completed after attendance of continuing education sessions held at NACCT. Individuals who do not complete within 30 days of the meeting will not receive continuing education credit through NABP."**

Application for nursing credits has been submitted to the California Board of Nursing. Nurses can earn up to a maximum of 38 continuing education credit hours. Contact hours will not be awarded for more than one concurrent session.

The American Academy of Clinical Toxicology is a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. The AAPCC Public Education Track is designated for Certified Health Education Specialists (CHES) to receive up to 13.5 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours available are 8 NCHEC Provider # 101772

(NOTE: Shaded areas denote concurrent sessions. Full credit will not be awarded for both sessions within a concurrent time block. Although poster sessions will be a part of the North American Congress of Clinical Toxicology 2017, except under special circumstances they will not be eligible for continuing education credit.)

Continuing Education Sessions				
Session	ACPE Program Number	MD	RN	RPH
October 11, 2017				
ACMT Pre-Symposium: Up for Debate: Addressing Controversies in Poisoning (am session)	0225-9999-17-200-L04-P (K)	3.5	3.5	3.5
ACMT Pre-Symposium: Up for Debate: Addressing Controversies in Poisoning (pm session)	0225-9999-17-250-H04-P (K)	4.5	4.5	4.5
October 12, 2017				
AACT Pre-Symposium: Cardiotoxins: An in-depth look at the Pathophysiology, Presentation, and Management of Heart Poisoning (am session)	0225-9999-17-201-L04-P (K)	3.5	3.5	3.5
AACT Pre-Symposium: Cardiotoxins: An in-depth look at the Pathophysiology, Presentation, and Management of Heart Poisoning (pm session)	0225-9999-17-251-L04-P (K)	3.5	3.5	3.5
ACMT Medical Toxicology: 19th Annual Clinical Pathologic Competition (CPC)	0225-9999-17-202-L04-P (K)	2	2	2
October 13, 2017				
NACCT Keynote Presentation: Open Science: Lessons from the Open-Source Outbreak	0225-9999-17-203-L04-P (K)	1	1	1
AAPCC Scientific Symposium: The Path to a Canadian Antidotes Registry	0225-9999-17-204-L04-P (K)	1	1	1
AACT Toxicology History Section Symposium	0225-9999-17-205-L04-P (K)	1	1	1
AACT Acute and Intensive Care Symposium	0225-9999-17-206-L04-P (K)	1.5	1.5	1.5
Lightning Orals Abstracts # 17-20	0225-9999-17-207-L04-P (K)	.5	.5	.5
AAPCC Veterinary Symposium: Tasty and Toxic? Species Differences (human and veterinary) in Food Toxicology	0225-9999-17-208-L04-P (K)	1	1	1
PEC: Health Promotion: Exploring Theories and Models that Relate to Health Behavior Change	0225-9999-17-209-L04-P (K)	1.5	1.5	1.5
Platform Session I Abstracts #1-8	0225-9999-17-210-L04-P (K)	2	2	2
PEC: Opioid Epidemic & Harm Reduction	0225-9999-17-211-L04-P (K)	1.75	1.75	1.75
AACT Toxicology Newshour Lecture: Recent Chemical Warfare (Cholinesterase Inhibitors) attacks in Syria	0225-9999-17-252-L04-P (K)	1	1	1
AACT Radiation Section Symposium: Acute Radiation Syndrome Update	0225-9999-17-212-L04-P (K)	1	1	1
SPI Best Practices Symposium: Poison Center Perspectives on the Opioid Crisis	0225-9999-17-214-L04-P (K)	1	1	1

NORTH AMERICAN CONGRESS
OF CLINICAL TOXICOLOGY 2017

SHERATON WALL CENTRE
VANCOUVER, BC
OCTOBER 11-15, 2017

AACT Pediatrics SIG & ACMT Addiction Medicine Symposium: The Impact of the Opioid Crisis on Children and Adolescents"	0225-9999-17-213-L04-P (K)	1.5	1.5	1.5
PEC: The Art of the Perfect Social Media Post and How to Analyze Its Success	0225-9999-17-215-L04-P (K)	1	1	1
October 14, 2017				
AACT Career Achievement Award Symposium	0225-9999-17-216-L04-P (K)	1	1	11
ACMT Scientific Symposium: Out of the Starting Gate: Medical Toxicology Research Study Design, Funding, and Patient Consent	0225-9999-17-217-L04-P (K)	1.5	1.5	1.5
SPI Roundtable Symposium	0225-9999-17-218-L04-P (K)	1.5	1.5	1.5
PEC Symposium: Marijuana: The Toke of the Town	0225-9999-17-219-L04-P (K)	1.5	1.5	1.5
APAMT Scientific Symposium: Prescription Medicine Misuse Outside North America	0225-9999-17-220-L04-P (K)	1.5	1.5	1.5
Lightning Orals Abstracts # 21-24	0225-9999-17-221-L04-P (K)	.5	.5	.5
PEC: Epidemiology for Non-Epidemiologists: Using Poison Center Data	0225-9999-17-222-L04-P (K)	1	1	1
AACT Debate: Benzodiazepines or Antipsychotics for the Acutely Violent, Intoxicated Patient"	0225-9999-17-223-L04-P (K)	1	1	1
Platform Session II Abstracts #9-12	0225-9999-17-224-L04-P (K)	1	1	1
AACT Occupational and Environmental Toxicology Section Symposium: Remediation and Sequelae of Oil Pipeline Spills	0225-9999-17-225-L04-P (K)	1	1	1
PEC AAPCC Updates	0225-9999-17-226-L04-P (K)	1	1	1
ACMT Practice Symposium: Groups, Tweets, and Friend Requests: Modern Marketing of Your Toxicology Expertise	0225-9999-17-227-L04-P (K)	1	1	1
AACT Herbals Section Symposium: Green Tea, the Good and the Ugly"	0225-9999-17-228-L04-P (K)	1	1	1
PEC Designing & Using Program Evaluations	0225-9999-17-229-L04-P (K)	1	1	1
ABAT Scientific Symposium: The Dark Web: Cyberspace Marketplace	0225-9999-17-230-L04-P (K)	1	1	1
ACMT Fellows - in - Training Visiting Professor: The Advantage of Developing a Niche for Your Medical Toxicology Career	0225-9999-17-231-L04-P (K)	1	1	1
PEC: Toxicology 101 for Public Educators: Common Pediatric Exposures	0225-9999-17-232-L04-P (K)	1	1	1

NORTH AMERICAN CONGRESS
OF CLINICAL TOXICOLOGY 2017

SHERATON WALL CENTRE
VANCOUVER, BC
OCTOBER 11-15, 2017

October 15, 2017				
AACT Scientific Symposium	0225-9999-17-233-L04-P (K)	1	1	1
PEC HRSA Updates	0225-9999-17-234-L04-P (K)	.75	.75	.75
CAPCC Scientific Symposium: Public Health Emergency: The British Columbia Experience with the Opioid Crisis	0225-9999-17-235-L04-P (K)	1	1	1
SPI Clinical Practice Symposium: The Cost of Treating the Poisoned Patient	0225-9999-17-236-L04-P (K)	1	1	1
PEC Marketing: Why Branding is Important	0225-9999-17-237-L04-P (K)	1	1	1
EAPCCT Scientific Symposium: Current Controversies in Pesticide Toxicology	0225-9999-17-238-L04-P (K)	1.5	1.5	1.5
Lightning Orals Abstracts #25-28	0225-9999-17-239-L04-P (K)	.5	.5	.5
PEC Tailored and Targeted Health Communication: Strategies for Enhancing Information Relevance for Children, for Adolescents, and for Senior Adults	0225-9999-17-240-L04-P (K)	1	1	1
AACT Forensics Section Symposium: Case Files for the Medical Examiners' Office	0225-9999-17-241-L04-P (K)	1	1	1
Platform Session III Abstract Sessions #13-16	0225-9999-17-242-L04-P (K)	1	1	1
AACT Fellows - in - Training Brief Oral Presentations	0225-9999-17-243-L04-P (K)	1	1	1
PEC Swap and Share	0225-9999-17-244-L04-P (K)	1	1	1
AACT Env Tox: Health Risk Assessment with Emphasis on a Lead Mine in Indonesia	0225-9999-17-245-L04-P (K)	.5	.5	.5
AACT Sports Tox Section Symposium: The Use of Performance Enhancing Drugs and Exercise Recovery in the Athlete	0225-9999-17-246-L04-P (K)	.5	.5	.5
Medical Toxicology 2017 LLSA Article Review	0225-9999-17-247-L04-P (K)	2	2	2
ACMT Fellows - in - Training Roundtable: Government Jobs and Opportunities for Medical Toxicologists	0225-9999-17-248-L04-P (K)	1	1	1
Toxicological Jeopardy for SPIs	0225-9999-17-249-L04-P (K)	1	1	1
	Maximum hours	38	38	38

"K" denotes knowledge-based activity; "A" denotes application-based activity

NORTH AMERICAN CONGRESS
OF CLINICAL TOXICOLOGY 2017

SHERATON WALL CENTRE
VANCOUVER, BC
OCTOBER 11-15, 2017

DISCLOSURE OF SIGNIFICANT RELATIONSHIPS WITH
RELEVANT COMMERCIAL COMPANIES/ORGANIZATIONS

The ACCME Standards for Commercial Support and ACPE Non-Commercialism Standards require presentations be free of commercial bias and that any information regarding commercial products / services be based on scientific methods generally accepted by the medical community. According to the American Academy of Clinical Toxicology “Policy on Non-Commercialism and Fair Balance”, all faculty, authors, editors, and planning committee members (including their immediate family members) participating in an AACT-sponsored activity are required to disclose **any relevant financial relationships with commercial interests**. A commercial interest is any entity, producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Providers of clinical service directly to patients are not commercial interests. Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria for promotional speakers’ bureau, ownership interest (e.g. stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considered relationships of the person involved in the CME activity to include financial relationships of a spouse or partner. *Contracted research* includes research funding where the institution gets the grant and manages the fund and the person is the principal or named investigator on the grant. There is no minimum dollar amount for relationships.

Should potential conflicts of interest be identified, AACT will resolve all conflicts of interest prior to the education activity being delivered to learners. Presentations offered by a person with a potential conflict of interest are required to submit a detailed outline of the presentation, which will be used by ACCT to confirm the scientific objectivity of the presentation. The audience will also be afforded the opportunity to evaluate whether the speaker’s interests or relationships influenced the presentation with regard to exposition or conclusion through the use of the program evaluation instrument. Faculty, authors, editors or planning committee members that do not provide disclosure are ineligible to participate in the continuing education activity.

This educational activity has been planned to be well-balanced and objective in discussion of available treatment regimens. Interpretations and opinions offered by the authors represent their viewpoints. Conclusions drawn by the participant should be derived from careful consideration of all available scientific information.

When therapeutic options are discussed, it is our preference that only generic names be used. If it is necessary to use a trade name, then those of several companies must be used, if available. Products may be discussed in the treatment of indications outside current approved labeling. Speakers are required to disclose this to the participants.

NORTH AMERICAN CONGRESS
OF CLINICAL TOXICOLOGY 2017

SHERATON WALL CENTRE
VANCOUVER, BC
OCTOBER 11-15, 2017

Speaker/Planner/Reviewer Financial Relationships

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to American Academy of Clinical Toxicology. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no relevant financial relationships.

Name (role)	Commercial Interest Name	Type of Relationship
William Banner/Speaker/Organizer	BTG	Consultant; Speakers Bureau
Rose Cairns/Speaker	Seqirus	Grant
Jon Cole/Organizer/Speaker	AcelRx Pharmaceuticals	Consultant
Spencer Greene/Speaker	BTG	Speakers Bureau
Kennon Heard/Speaker/Organizer	McNeil Consumer Healthcare	Contracted Research
Kenneth McMartin/Speaker	Mericon Investment Group	Royalty
S Todd Mitchell/Speaker	Mylan Pharmaceuticals	Consultant

Acknowledgment of Commercial Support

BTG International Inc.

North American Congress of Clinical Toxicology

Organized By The American Academy of Clinical Toxicology



ONLINE LIBRARY

www.prolibraries.com/nacct

SHERATON VANCOUVER WALL CENTRE • OCTOBER 13-15, 2017

INCLUDES:

Pre-Conference

- Syllabus Handouts

On-site

- Online Evaluations/
CME Contact Hours

Post-Conference

- 2017 Conference Sessions
- Live Audio Recordings
- Search by Keywords
- Download CME Certificate
- Access Anytime, Anywhere

The space below is provided for you to enter your existing Prolibraries username and password for future use.

Username

Password

Conference Access Code

NACCT17

Deadline for Evaluations
11/15/2017

FREE ACCESS & EVALUATION INSTRUCTIONS:

1. Log in using your NACCT Online Library (www.prolibraries.com/nacct) Username and Password. (If you do not have an account, click "Create Account" and fill out the appropriate information.)
2. Redeem the Code: **NACCT17** Click on "Add Conference Code" under "Your Account."
3. Verify attendance by providing your name and e-mail address.
4. Click on "Session Evaluations."
5. Select the session you need to evaluate.
6. Complete the evaluation, and click "submit." Make sure you fill in the evaluation completely as the contact hours are not earned until the entire evaluation is completed.
7. Complete the Overall Convention Evaluation by clicking on "Conference Evaluation."

Visit the Digitell booth in the Lower Lobby for an on-site demonstration

Technical Support: 877-796-1325 | Other Inquiries: 800-679-3646 | Visit: www.prolibraries.com/nacct

ONLINE LIBRARY


www.prolibraries.com/nacct

Complete the Paperless Evaluation Process and
Access Your CE Certificate in NACCT's Online Library

Conference Access Code: NACCT17

How to Receive Continuing Education (CME) Credit

- Attend at least 90% of each session to receive contact hours.
- Complete an evaluation (in NACCT's Online Library) for EACH session you attend by following the instructions on the previous page.
- Please note that in order to obtain contact hours for the sessions you attended in Vancouver, you must complete the online evaluation process by November 15th, 2017.



Evaluation Deadline Date: November 15th, 2017

Obtain Your CE Certificate

Your CE certificates/transcript for this Congress can be accessed by clicking on "CE Transcript" under "Your Account." Please note that you will be able to access and print your certificate at any time after you have completed the evaluation process.

Your continuing education (CE) records for the Congress may be printed as needed from the NACCT Online Library (www.prolibraries.com/nacct) in the CE Transcript section.

CE Transcript



IMPORTANT: In order to obtain contact hours for the sessions you attended, you MUST complete the online evaluation process by November 15th, 2017.

Visit the Digitell booth in the Lower Lobby for an on-site demonstration

Technical Support: 877-796-1325 | Other Inquiries: 800-679-3646 | Visit: www.prolibraries.com/nacct



North American Congress of Clinical Toxicology

Vancouver, BC Canada

October 11-15, 2017

Attention All SPIs



❖ The SPI Committee meeting

Port Alberni 4th floor North Tower 10/12/17 4:00 pm to 7:00 pm

❖ SPI "Meet and Greet"

Beluga 3rd Floor South Tower 10/12/17 7:30 pm to 9:00 pm

❖ The SPI Best Practice Symposium:

Poison Center Perspectives on the Opiate Crisis

Junior Ballroom C 3rd floor North Tower Monday 10/13/17 3:30pm- 5:00pm

❖ Quiz Bowl

Grand Ballroom AB Monday 10/13/17 6:00pm- 8:00pm

❖ SPI Roundtable

Junior Ballroom C 3rd Floor North Tower Tuesday 10/14/17 8:30 am to 10:00 am

❖ SPI Clinical Practice Symposium:

The Cost of Treating the Poisoned Patient

Grand Ballroom CD 10/15/17 8:30am -09:30am

- All SPIs are invited to attend the many events being held at NACCT.
- Come connect with other SPIs from across the nation.
- We are a collaborative group that welcomes your participation.
- Please do not forget to download the 2017 NACCT App.



For more details please contact
Rosemary Smaglick, RN, CSPI
Rsmaglick@chw.org



The AAPCC Public Education Committee (PEC) Presents: NACCT 2017 Education Track

Educators welcome all poison center staff to participate in PEC sessions. Together, we can improve the understanding of poison centers and poison safety in our communities.

Health Promotion: Exploring Theories and Models that Relate to Health Behavior Change (interactive working session).

Friday, October 13, 11 am – 12:30 pm

A health communications expert from Simon Fraser University will discuss different models and applications of health promotion techniques and how to use these theories in practice.

Opioid Epidemic and Harm Reduction

Friday, October 13, 1:30 – 3:15 pm

An expert panel from the Vancouver area will discuss ongoing approaches and strategies to the opioid problem in their communities and how harm reduction may reduce instances of morbidity and mortality among these populations.

Marijuana: The Toke of the Town

Saturday, October 14, 8:30 – 10 am

Join us to learn more about the health risks and the benefits of marijuana from a panel of experts as they share their perspectives.

Medical,
nursing and
pharmacy
credits are
are available
for all PEC
sessions.

See the NACCT
schedule for all
PEC session
details



North American Congress of Clinical Toxicology

Organized By The American Academy of Clinical Toxicology

CHICAGO, IL

PRE-MEETING OCTOBER 25-26, 2018

MAIN CONGRESS 27-29, 2018

HYATT REGENCY CHICAGO



SAVE THE DATE

Sponsored By:

- American Academy of Clinical Toxicology
- American Association of Poison Control Centers

Annual Meeting of:

- American Academy of Clinical Toxicology
- American Association of Poison Control Centers
- American College of Medical Toxicology
- Canadian Association of Poison Control Centres
- European Association of Poisons Centres and Clinical Toxicologists



NACCT

